Selexys Pharmaceuticals? pioneering work on the molecular mechanisms of inflammation has led to breakthroughs in novel therapeutics for inflammatory and thrombotic diseases and positioned Selexys with strong scientific underpinnings.
Charlesson, an Oklahoma-based pharmaceutical company, is actively engaged in the development of therapeutics for treating debilitating ophthalmic diseases. Their product pipeline includes pharmaceutical treatments for Age-Related Macular Degeneration, Diabetic Retinopathy, Ocular Inflammation, Angiogenesis, and systemic diabetes.
DormaTarg is a pharmaceutical company developing a series of small molecule oncology therapeutics that inhibit recurrence in metastasis prone cancers, with an initial focus on Triple Negative Breast Cancer.
Drik is a pre clinical toxicology services laboratory for drug safety evaluation. They do preclinical screening tests for cosmetic industry and non clinical toxicology testing for chemical manufacturing.
EpimedX, LLC is an Oklahoma-based biotechnology company with the mission to develop Gene Regulation Therapy ? a promising technology that is expected to provide a safe, cost-effective and permanent treatment for sickle cell disease, beta-thalassemia and malaria without dangerous or harmful side effects.
Hyalose, LLC is a biotechnology company focused on the commercialization of unique recombinant technologies for producing Hyaluronic Acid (HA), an important biomolecule for many healthcare and cosmetic applications.
Moleculera Labs provides personalized clinical testing services for individuals suspected of suffering from PANDAS/PANS, which are treatable neurologic conditions that may be associated with motor tics, obsessive compulsive disorders (OCD) and sometimes Autism Spectrum Disorders.
Otologic Pharmaceutics, Inc. (OP) is an Oklahoma-headquartered organization formed specifically to commercialize promising technologies that address novel pharmacological solutions for hearing and balanced health.
Synereca Pharmaceuticals was created to address the growing problem of bacterial resistance to current antibiotics by developing orally active drugs that restore or increase the effectiveness of existing antibiotics.?